Inve India ▾

Venus Remedies share price & results

Venus Remedies Limited· Healthcare

Results to
Sept 2026
Ownership as of
Sept 2026

Panchkula-based pharma manufacturer of critical-care injectables & generics, sold in 90+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue219 ₹ crore+13.5% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin21.0 %+6.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit29.0 ₹ crore+52.6% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity17.47 %+10.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin15.40 %+4.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)19.23 %+10.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Price

₹1,388.8 −4.99% · −₹73

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +214.9% 1Y

₹0.5k₹1.0k₹1.5k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹441 on 24 Oct 2025 → ₹1,388.8. High ₹1,947 (25 Jun 2026), low ₹434.35 (31 Oct 2025).

Previous close
₹1,461.8
Market cap
₹2.0k Cr
52-week range
₹434.35 – ₹1,947
One year
+217.22%
Price to earnings (TTM to Sept 2026)
15.89×
Return on equity (TTM to Sept 2026)
17.47%

Overview

Symbol
NSE:VENUSREM
Exchange
NSE
Currency
INR

What Venus Remedies Limited does

Based on the company's own presentations, annual report and earnings calls.

Venus Remedies is a research-led pharmaceutical manufacturer headquartered in Panchkula, India, producing generic and speciality injectable and oral formulations across antimicrobial resistance (AMR), oncology, skin and wound care, neurology, pain management, anticoagulants, herbal therapeutics and disinfectants. It runs its own manufacturing units in India, plus Venus Pharma GmbH in Germany, and an in-house DSIR-accredited R&D centre, the Venus Medicine Research Centre (VMRC), which develops proprietary platforms such as Renal Guard Technology for anti-infectives. It earns through direct sales, government/institutional tenders (e.g., UNICEF, PAHO) and regulatory-approval-driven exports across 90+ countries, alongside a domestic trade-generics network of stockists and retailers. A plant-based wellness brand, RESET, sits alongside its core prescription and critical-care portfolio.

Segments

  • Domestic formulations (Trade Generics)
  • International business
  • Consumer wellness (RESET)
Global presence
90+ countries
Manufacturing facilities
3 (India, plus Venus Pharma GmbH, Germany)
Installed injectable manufacturing capacity
100 mn units per annum
Marketing authorisations held
1,050+
Product basket
180+ formulations
Hospital reach
12,000+ hospitals
Founded 1989Headquarters Panchkula, India Company website

Your own record

Start an Inve Case for Venus Remedies Limited

Free account: one company. Everything above stays public.

Write why you follow Venus Remedies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Venus Remedies Limited

Guides on how to read this kind of business and the numbers that matter.